Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 - Episode 2
Panelists discuss how comprehensive molecular profiling and biomarker testing are critical for guiding targeted therapy decisions in advanced biliary tract cancer (BTC), citing recent real-world data presented at ASCO GI that demonstrated improved outcomes with matched targeted therapies.
Video content above is prompted by the following: